Eli Lilly and Company $LLY Stock: King Luther Capital Management Corp Grows Holdings

King Luther Capital Management Corp grew its position in shares of Eli Lilly and Company (NYSE:LLY) by 2.0% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 212,351 shares of the company’s stock after buying an additional 4,148 shares during the quarter. Eli Lilly and Company makes up approximately 1.0% of King Luther Capital Management Corp’s portfolio, making the stock its 21st largest holding. King Luther Capital Management Corp’s holdings in Eli Lilly and Company were worth $245,707,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Marshall & Sterling Wealth Advisors Inc. boosted its position in shares of Eli Lilly and Company by 60.0% in the 1st quarter. Marshall & Sterling Wealth Advisors Inc. now owns 40 shares of the company’s stock valued at $37,000 after purchasing an additional 15 shares during the period. Torren Management LLC grew its stake in Eli Lilly and Company by 357.1% during the 3rd quarter. Torren Management LLC now owns 32 shares of the company’s stock worth $37,000 after buying an additional 25 shares during the last quarter. AlphaCentric Advisors LLC acquired a new position in Eli Lilly and Company during the first quarter worth approximately $42,000. Foresight Capital Management Advisors Inc. acquired a new position in Eli Lilly and Company during the third quarter worth approximately $49,000. Finally, Caitlin John LLC purchased a new stake in Eli Lilly and Company in the second quarter valued at approximately $64,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $1,437.46 on Thursday. The firm’s fifty day moving average price is $1,231.13 and its 200 day moving average price is $1,106.42. Eli Lilly and Company has a 1-year low of $850.51 and a 1-year high of $1,453.00. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.39 and a quick ratio of 1.00. The firm has a market cap of $1.35 trillion, a price-to-earnings ratio of 46.66, a price-to-earnings-growth ratio of 1.72 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.71 by $1.77. The company had revenue of $24.40 billion for the quarter, compared to analysts’ expectations of $22.58 billion. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. Eli Lilly and Company’s revenue was up 38.6% compared to the same quarter last year. During the same period in the previous year, the company posted $7.02 EPS. On average, sell-side analysts expect that Eli Lilly and Company will post 35.67 EPS for the current year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Friday, November 13th. This represents a $6.92 annualized dividend and a dividend yield of 0.5%. Eli Lilly and Company’s payout ratio is presently 22.46%.

Trending Headlines about Eli Lilly and Company

Investors following LLY have been watching these headlines:

• Positive Sentiment: A recent report says Lilly raised its 2026 sales outlook to as much as $92 billion, reinforcing expectations that strong demand for its obesity and diabetes medicines can drive continued growth. Article: Lilly’s 2026 sales outlook
• Negative Sentiment: The FDA is requiring GLP-1 drugmakers to add a warning about rare NAION-related vision loss. Zepbound is among the medicines affected, creating a potential safety concern for Lilly’s key product category. Article: FDA warning on GLP-1 drugs
• Negative Sentiment: Possible new U.S. drug-price negotiations could put pressure on Lilly revenue, according to a report identifying the company as facing nearer-term pricing exposure. Article: Drug-pricing risks

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on LLY shares. Morgan Stanley increased their price objective on Eli Lilly and Company from $1,430.00 to $1,596.00 and gave the company an “overweight” rating in a report on Friday, October 30th. Jefferies Financial Group raised their target price on shares of Eli Lilly and Company from $1,610.00 to $1,700.00 and gave the stock a “buy” rating in a research report on Monday. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $1,413.00 target price on shares of Eli Lilly and Company in a report on Tuesday, October 20th. Berenberg Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and set a $1,400.00 price target for the company in a research report on Tuesday, September 15th. Finally, BMO Capital Markets reiterated an “outperform” rating and issued a $1,650.00 price target on shares of Eli Lilly and Company in a research report on Friday, October 30th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average price target of $1,416.64.

Insider Transactions at Eli Lilly and Company

In related news, EVP Anat Hakim sold 5,000 shares of the firm’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total value of $7,012,600.00. Following the completion of the sale, the executive vice president owned 4,137 shares in the company, valued at $5,802,225.24. This trade represents a 54.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the sale, the executive vice president directly owned 54,147 shares in the company, valued at $63,628,139.70. This represents a 10.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.14% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.